![](images/graphics/blank.gif)
Idiopathic pulmonary fbrosis
-
Although antifibrotic drugs, including nintedanib and pirfenidone, slow the progression of idiopathic pulmonary fbrosis (IPF), there is little data about the timing of start of antifibrotic treatment in real-world clinical practice. The present study aimed to clarify the efficacy of nintedanib and pirfenidone in patients with early-stage IPF.
10p
vimackenziebezos
29-11-2021
13
0
Download
-
Nintedanib reduces the rate of decline in forced vital capacity in patients with idiopathic pulmonary fbrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). The recommended dose of nintedanib is 150 mg twice daily (BID).
13p
vimackenziebezos
29-11-2021
14
0
Download
-
Idiopathic Pulmonary Fibrosis is a chronic, progressive interstitial lung disease for which there is no cure. However, lung function decline, hospitalizations, and mortality may be reduced with the use of the antifibrotic medications, nintedanib and pirfenidone.
14p
vimackenziebezos
29-11-2021
9
0
Download
-
Remodeling of the extracellular matrix (ECM) is a central mechanism in the progression of idiopathic pulmonary fbrosis (IPF), and remodeling of type VI collagen has been suggested to be associated with disease progression. Biomarkers that defect and predict the progression of IPF would provide valuable information for clinicians when treating IPF patients.
8p
vimackenziebezos
29-11-2021
6
0
Download
-
Interstitial lung disease is a debilitating condition associated with significant dyspnoea, fatigue, and poor exercise tolerance. Pulmonary rehabilitation is an effective and key intervention in people with interstitial lung disease.
9p
vimackenziebezos
29-11-2021
8
1
Download
-
Supplemental oxygen delivered with standard oxygen therapy (SOT) improves exercise capacity in patients with idiopathic pulmonary fbrosis (IPF). Although high-fow nasal cannula oxygen therapy (HFNC) improves oxygenation in other respiratory diseases, its impact on exercise performance has never been evaluated in IPF patients.
9p
vimackenziebezos
29-11-2021
6
1
Download
-
It is not well-known if diagnosing and treating sleep breathing disorders among individuals with idiopathic pulmonary fbrosis (IPF) improves health outcomes. We evaluated the association between receipt of laboratory-based polysomnography (which is the first step in the diagnosis and treatment of sleep breathing disorders in Ontario, Canada) and respiratory-related hospitalization and all-cause mortality among individuals with IPF.
12p
vimackenziebezos
29-11-2021
5
1
Download
-
Previous studies suggest that transient receptor potential (TRP) channels and neurogenic inflammation may be involved in idiopathic pulmonary fbrosis (IPF)-related high cough sensitivity, although the details of mechanism are largely unknown.
14p
vimackenziebezos
29-11-2021
7
0
Download
-
Currently, there are two antifbrotics used to treat idiopathic pulmonary fbrosis (IPF): pirfenidone and nintedanib. Antifbrotics slow disease progression by reducing the annual decline of forced vital capacity (FVC), which possibly improves outcomes in IPF patients.
13p
vimackenziebezos
29-11-2021
7
2
Download
-
Idiopathic pulmonary fbrosis (IPF) is a chronic progressive disease that causes scarring of the lungs. The disease is associated with the usual interstitial pneumonia pattern, which was not yet fully recapitulated by an animal model.
6p
vimaine2711
26-03-2021
7
2
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)